Squandered Momentum? How the EU's Response to US Science Funding Chaos Fell Short

2025 proved a tumultuous year for the global research community. In the United States, administrative policies led to widespread disruptions in federal science funding, with thousands of grants terminated or frozen at agencies such as the National Institutes of Health (NIH) and National Science Foundation (NSF). Reports indicate that roughly 2,600 grants remained unfrozen by late 2025, amounting to about $1.4 billion in unspent funds, while broader actions affected over 7,800 grants overall. This created profound uncertainty for US scientists and institutions, sparking fears of a potential brain drain.

The chaos presented a rare opportunity for the European Union to attract top talent, reverse longstanding outflows of researchers, and narrow the innovation gap—particularly in life sciences, where Europe already trails the US significantly. Having worked across both continents, the disparity in life-sciences research capacity is stark: Europe often lacks the scale, speed, and funding coherence to compete at the same level. EU leaders responded boldly, with the European Commission announcing the "Choose Europe for Science" initiative—a €500 million (~$556 million) package over 2025–2027 to support relocating researchers, alongside extensions to existing schemes. Yet, nearly a year later, has this translated into meaningful gains?

Grand Promises in 2025, Glacial Progress in 2026

The short answer is no. The EU's bureaucratic structures—decentralized across member states, slow to adapt, and ill-suited to the rapid pace of 21st-century research—have hindered decisive action, much as they have in other high-stakes fields like artificial intelligence.

The "Choose Europe for Science" program sounded promising, with features such as job portals, extended European Research Council grants (from 5 to 7 years in some cases), and reinforced calls. In late 2025, the Marie Skłodowska-Curie Actions (MSCA) announced over €1.25 billion for 2026, including a second wave of Choose Europe funding (€51.25 million reinforced) to address researcher precarity and promote brain gain. Additional MSCA efforts, such as postdoctoral fellowships and staff exchanges, targeted international collaboration, with life sciences featuring prominently in awarded projects. Yet as of March 2026, widespread reports of disbursed grants or large-scale talent relocations remain scarce. Some MSCA postdoc initiatives rolled out, but many awards are still pending or in early stages.

Initial interest spiked amid the US turmoil. A Nature poll in early 2025 found that 75% of responding US scientists—more than 1,200 out of over 1,600 participants—were considering leaving the country, with many eyeing Europe or Canada. The research boat had been rocked, but Europe failed to steer it ashore.

No Prizes for Third Place

While global attention fixates on economic turbulence and geopolitical conflicts, scientific progress continues unabated. Breakthroughs in life sciences and other fields can deliver economic advantages and alleviate resource pressures—making talent attraction a strategic imperative.

Who ultimately benefited most from the US disruptions? Several nations moved aggressively. China intensified its efforts through over 200 government-backed programs, launching initiatives like the "K visa" in October 2025 to attract young STEM talent without requiring job offers. By late 2025, around 950,000 foreign professionals were active in China, up notably from pre-pandemic levels, bolstering its tech and research ecosystem.

Surprisingly, the US retained its dominance as the top destination for highly skilled talent. According to a 2025 BCG report on global talent mobility, the US strengthened its market share (gaining 2.4 percentage points for highly skilled workers and more for STEM), even amid slowdowns elsewhere. Emerging hubs like the UAE also surged, but Europe saw further outflows: the same analysis highlighted the EU's inability to deliver on funding promises, exacerbating brain drain.

In February 2026, the US Congress rejected many of the administration's proposed sweeping cuts to science agencies, restoring funding closer to prior levels for NIH, NSF, and others. This narrowed the window for meaningful EU intervention. The narrow opportunity—when uncertainty peaked—slipped away.

Is It Too Late for Europe to Rejoin the Race?

Probably not entirely, but the path forward demands ruthless prioritization rather than diffuse efforts. On paper, Europe's resources allocated to innovation remain competitive with those of the US or China in aggregate terms. Yet spreading them thinly across multiple sectors dilutes impact and perpetuates lag in critical areas such as life sciences and emerging technologies like artificial intelligence.

To close the gap in at least one high-priority domain, the EU should concentrate investments where it holds comparative advantages—such as strong intellectual property frameworks in collaborative research networks or regulatory expertise in biotechnology. In addition, Europe should not hesitate to adopt proven practices from the US. For instance, significantly simplify regulations and accelerate grant application processes (ideally reducing timelines to months rather than the current extended periods under Horizon Europe). Average grant sizes must also increase to support ambitious outcomes: while European Research Council Starting Grants cap at around €1.5M total (often ~€300K–€500K annually over 5 years), US National Institutes of Health R01 awards in life sciences commonly reach $500K–$600K per year, enabling larger-scale, high-risk projects.

Reforms should further target private-sector investment. Europe's venture capital in biotech lags far behind the US, which commands roughly 63% of global life-sciences venture funding (with annual totals often exceeding $19–27 billion in recent years), compared with Europe's share of just 7%. Tax incentives and streamlined mechanisms could redirect private capital toward high-potential biotech ventures, addressing this structural shortfall.

Leverage advantages in the speed of visa pathways for relocating scientists. Processing times for EU researcher visas or the EU Blue Card average 6–12 weeks in many member states, providing greater predictability than US routes such as the H-1B visa, which is hampered by annual caps, lottery systems, and delays often extending to 3–6 months or longer. Public–private partnerships, combined with deeper integration—perhaps through centralized funding pots for targeted 'moonshot' programs—could help overcome the pitfalls of decentralization.

Collaboration remains essential. Isolation risks further marginalization in a global "talent war" where ideas circulate freely across borders. By focusing sharply, fostering international ties, and acting with urgency, Europe could yet transform squandered momentum into sustained competitiveness. The alternative—continued drift—would leave the continent watching from the sidelines as others define the future of discovery.